VIDAC PHARMA HOLDING PLC
Commented by Juliane Zielonka on October 3rd, 2024 | 14:00 CEST
Vidac Pharma, BioNTech, Gerresheimer optimize the value chain - From research to patient
Medical innovation and rapid therapy development are gaining momentum thanks to the use of AI. In this context, companies in the pharmaceutical and biotech industry are relying on groundbreaking technologies and strategies to optimize the value chain from research to patient. Vidac Pharma is researching an innovative approach to fighting cancer by supporting the body's own immune defenses. The Company has now received a patent in the US, granting exclusivity. BioNTech is using AI-powered research to bring innovative therapies to patients more quickly. Gerresheimer is producing advanced packaging solutions for pharmaceuticals that have the potential to improve healthcare significantly. We take a look at current annual reports and value chains.
Read
Commented by André Will-Laudien on September 16th, 2024 | 07:15 CEST
This is unbelievable! 250% with an announcement: Bayer, Vidac Pharma, Evotec, and Valneva
The stock market has been rallying week after week, yet the biotech sector stubbornly lags behind. However, with the first interest rate cut in Europe, the path of lower financing options has now also been mapped out for the US. This week, the FED is set to decide on rate cuts, with 87% of capital market experts expecting a total of three cuts by the end of the year. That would be grist to the mill for growth stocks. Vidac Pharma has already gained 50% in 2 months, and Bayer and Evotec will likely follow soon. Valneva is raising EUR 61 million and aims to break even operationally. What is next for the sector?
Read
Commented by Fabian Lorenz on September 11th, 2024 | 07:00 CEST
Multiplication and travel boom! Bayer, TUI, Vidac Pharma
Vidac Pharma shares have gained over 23% in the past four weeks. Driven by strong study data from the biotech company focused on fighting cancer, analysts even see the potential for multiplication. Such euphoria has been absent at Bayer for some time. However, at least there is positive momentum from the pharmaceuticals division again, which is much needed, as the Leverkusen-based company's pipeline is considered modest. In contrast, business at TUI is booming. Nevertheless, the tourism group's shares have disappointed in the current year. Will a new cruise ship take it towards EUR 10?
Read
Commented by Armin Schulz on September 4th, 2024 | 07:30 CEST
Bayer, Vidac Pharma, BioNTech - Healthcare sector on the verge of a renaissance
Promising signs of a renaissance in the healthcare sector have emerged in recent months. Innovative start-ups are driving the digital transformation forward despite a decline in investment, as evidenced by the Digital Health Radar 2024. In Germany, Federal Health Minister Karl Lauterbach has introduced significant legislative reforms by July 2024, such as the introduction of electronic patient records and e-prescriptions. Complemented by increased M&A activity and technological integration through telehealth and AI, experts anticipate significant long-term growth potential despite the challenges faced in 2023. These developments point to a promising future for the healthcare sector. We take a look at three exciting candidates.
Read
Commented by Stefan Feulner on August 28th, 2024 | 07:15 CEST
Siemens Healthineers, Vidac Pharma, Viking Therapeutics - Powerful movements
After the hype during the COVID-19 pandemic, biotech stocks have lagged behind the broader market, allowing major technology companies to take the lead. Smaller, capital-intensive companies, in particular, have suffered from the high interest rate level. However, this is likely to change soon. On the one hand, monetary policy is expected to be eased, and on the other hand, demographic changes point to a long-term explosion in demand for new medications.
Read
Commented by Juliane Zielonka on August 23rd, 2024 | 07:15 CEST
Vidac Pharma, Bavarian Nordic, Palantir - Dream team in travel health and AI: 3 companies in focus
According to Marketresearch.biz, the travel health market is experiencing considerable growth. It is expected to grow from USD 78.5 billion in 2022 to USD 475.8 billion by 2032. This corresponds to an impressive annual growth rate of 20.3% between 2023 and 2032. Travel health can mean avoiding skin cancer while on vacation, but if it does occur, Vidac Pharma is at the forefront with a personalized medicine approach that excites investors. Listening to the WHO, it is clear that monkeypox is once again spreading and posing health risks. As a German-Danish biotech company, Bavarian Nordic has the vaccine answer and is revising its forecasts upwards thanks to strong market demand. Anyone travelling should also keep an eye on geopolitical tensions. Palantir has recently made a name for itself by supporting governments with AI products. Now, Palantir is bringing on board a man with an immense track record in US politics. Today, we focus on three promising investment opportunities.
Read
Commented by André Will-Laudien on August 5th, 2024 | 07:00 CEST
In the fight against cancer - 100% performance possible: Bayer, Vidac Pharma, Evotec, BioNTech and CureVac
The FED is giving new hope to the Biotech sector with lower interest rates, which are expected to happen as early as September. This is important for the near future, as share prices are lagging dramatically behind the NASDAQ performance in 2024. However, if extensive research can be financed under more favourable conditions, this should also help the stock market prices recover. The business models contain some good news, and selection is now crucial. We assist in selecting attractive stocks and provide entry levels.
Read
Commented by Stefan Feulner on July 30th, 2024 | 06:30 CEST
Viking Therapeutics, Vidac Pharma, Merck KGaA - In the footsteps of Novo Nordisk
Drugs for the treatment of diabetes and obesity have helped the pharmaceuticals manufacturer Novo Nordisk to become the most valuable listed company in Europe. But the competition is not sleeping. Many promising biotechs are already presenting new preparations that could overtake the Danes in the long term. Young companies with the chance of the next blockbuster also have great potential in other areas, such as cancer research.
Read
Commented by Fabian Lorenz on July 24th, 2024 | 06:30 CEST
BioNTech, Bayer, Vidac Pharma: Buy recommendations and potential worth billions
Can BioNTech shares stop the downward trend? A "Buy" recommendation gives hope. According to this recommendation, the shares of the German biotech flagship have the potential to double in value. Analysts believe a multiplication is possible for Vidac Pharma. The biotech company is pursuing a revolutionary approach in the fight against cancer, and the first drug has a revenue potential of over EUR 1 billion. Even though research is still ongoing, Vidac is not expensive with a market capitalization of less than EUR 10 million, and is a takeover candidate if the study data remain positive. Analysts do not currently see any impetus for an increase in Bayer's share price. However, shareholders should be ready for news from the pharmaceutical pipeline in the coming weeks. These are important for the DAX-listed company.
Read
Commented by Juliane Zielonka on July 5th, 2024 | 07:35 CEST
Vidac Pharma, BioNTech, GSK: Pioneers in medical progress - Who will win the race?
With around 20 million cancer diagnoses worldwide each year, innovative therapeutic approaches are urgently needed. Companies such as Vidac Pharma are currently developing new ways of treating cancer that could lead to a groundbreaking breakthrough. The reason for this is the discovery of a particular enzyme and its mode of action. At the same time, a patent dispute is raging between Moderna and BioNTech, which could significantly impact the future of mRNA technology. This makes the strategic partnership between GSK and CureVac all the more important. The British company GSK is paying billions of euros for rights to COVID-19 and flu vaccines, which CureVac is to develop. During the pandemic, CureVac was noted more for its shortcomings in vaccine development. Will they achieve a breakthrough now?
Read